How does vitrakvi treat trk fusion positive cancer?

What is trk fusion positive cancer and how does vitrakvi treat it?

Trk fusion positive cancer is a type of cancer that occurs when a gene called TRK is fused with another gene. This fusion occurs as a result of a rearrangement or duplication of genetic material and can lead to the development of cancer. Vitrakvi (larotrectinib) is a targeted therapy that specifically targets and inhibits the TRK protein associated with these fusion genes.

Who does vitrakvi benefit and how does it work?

Vitrakvi has demonstrated significant efficacy in treating patients with metastatic TRK fusion cancer, regardless of the tumor type, tissue of origin, or age of the patient. The medication works by blocking the activity of the TRK protein, which is responsible for signaling the growth and spread of cancer cells. By inhibiting this signaling pathway, vitrakvi slows down or stops the growth of cancer cells.

What are the benefits and potential side effects of vitrakvi treatment?

According to studies and clinical trials, vitrakvi has shown promising results in patients with metastatic TRK fusion cancer, with a response rate of around 75%. The most common side effects of vitrakvi include fatigue, nausea, vomiting, diarrhea, and changes in liver function tests. Less common but more serious side effects can include severe infusion reactions, liver damage, and pancreatitis.

How long can patients with trk fusion positive cancer live with vitrakvi treatment?

While the exact duration of treatment and overall survival benefits of vitrakvi in patients with trk fusion positive cancer are still being studied, clinical trials have demonstrated that patients receiving vitrakvi can achieve long-lasting responses, with some patients experiencing disease control for more than a year.

[1] DrugPatentWatch.com. Vitrakvi (larotrectinib).

Sources:

1. DrugPatentWatch.com. Vitrakvi (larotrectinib).
2. National Cancer Institute. Larotrectinib.
3. ClinicalTrials.gov. Larotrectinib in Advanced Solid Tumors With NTRK Gene Fusions.